16 completed, 3 unknown, 2 terminated, 1 withdrawn. 7 Phase 3, 7 Phase 4, 4 Not applicable, 2 Phase 1, 2 Phase 2.
Follow calcium acetate: new trials by email Literature Review of calcium acetate trials Research Report on calcium acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acetate and Age-associated Arterial Dysfunction Calcium Acetate Oral Solution, Calcium Carbonate Oral Suspension - Aging, Vascular Stiffness | Phase 2 | Completed | University of Colorado, Denver | 37 | 2022-09-29 | 2026-08-31 |
| Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders Tecovirimat, sevelamer carbonate oral tablet, sucroferric oxyhydroxide chewable tablet - Smallpox | Phase 4 | Completed | SIGA Technologies | 44 | 2022-06-08 | 2026-09-11 |
| Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat Vadadustat, Sevelamer carbonate, Calcium acetate - Healthy Volunteers | Phase 1 | Completed | Akebia Therapeutics | 54 | 2020-06-15 | 2020-10-08 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| Hyperphosphatemia in Children With Chronic Kidney Disease Calcium acetate and sevelamer hydrochloride - Hyperphosphatemia | Phase 3 | Unknown | Assiut University | 40 | 2017-08-01 | 2017-06-28 |
| A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia PA21 (Velphoro®), Calcium Acetate (Phoslyra®) - Hyperphosphatemia | Phase 3 | Terminated | Vifor Fresenius Medical Care Renal Pharma | 85 | 2016-05-26 | 2019-09-10 |
| Optimal Anemia Treatment in End Stage Renal Disease (ERSD) standard care, Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D - Hyperparathyroidism, Secondary | Not applicable | Unknown | Azienda Ospedaliera Sant'Anna | 50 | 2015-03-01 | 2015-09-15 |
| Arterial Stiffness and Calcifications in Haemodialysis Patients on Sevelamer or Calcium Acetate Calcium acetate, Sevelamer - Haemodialyzed Patients, Hyperphosphatemia | Not applicable | Withdrawn | Romanian Society of Nephrology | 2012-01-01 | 2017-12-22 | |
| Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients Calcium acetate oral solution (COS), Sevelamer carbonate - Chronic Kidney Disease | Phase 4 | Completed | Fresenius Medical Care North America | 38 | 2011-09-01 | 2016-01-14 |
| Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction Diet counseling, Phosphorus binder - Chronic Kidney Disease | Phase 3 | Unknown | Salem Veterans Affairs Medical Center | 120 | 2011-06-01 | 2012-06-12 |
| Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4 Sevelamer carbonate, Calcium acetate - Chronic Kidney Disease | Phase 4 | Terminated | Albany College of Pharmacy and Health Sciences | 30 | 2011-01-01 | 2016-01-14 |
| A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis ferric citrate, ca acetate, sevelamer carbonate, placebo - Hyperphosphatemia, Kidney Failure | Phase 3 | Completed | Keryx Biopharmaceuticals | 441 | 2010-10-01 | 2014-12-10 |
| Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion. Calcium acetate, Iron Hydroxide Adipate, Placebo - Healthy, Chronic Kidney Diseases | Early Phase 1 | Completed | Medical Research Council | 30 | 2009-04-01 | 2017-02-06 |
| A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate - Chronic Kidney Disease | Not applicable | Completed | Denver Nephrologists, P.C. | 148 | 2009-02-01 | 2012-10-30 |
| Bioequivalence Study Comparing Calcium Acetate Oral Solution Versus Calcium Acetate Gelcaps in Healthy Volunteers Calcium Acetate Oral Solution 667 mg per 5 mL, Calcium Acetate 667 mg GelCaps, Calcium Citrate 950 mg Caplets - Hyperphosphatemia | Phase 1 | Completed | Fresenius Medical Care North America | 46 | 2008-08-01 | 2009-02-09 |
| Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) Sevelamer, calcium acetate - We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients. | Phase 4 | Completed | Gulhane School of Medicine | 100 | 2008-01-01 | 2011-07-22 |
| Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients Sevelamer HCl, Calcium-based phosphate binder - Hemodialysis, Hyperphosphatemia | Phase 4 | Completed | Chugai Pharma Taiwan | 166 | 2007-06-01 | 2014-08-05 |
| EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease) calcium acetate, placebo - Hyperphosphatemia, Kidney Failure | Phase 3 | Completed | Nabi Biopharmaceuticals | 110 | 2005-05-01 | 2008-01-08 |
| CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients calcium acetate, sevelamer, atorvastatin - Calcinosis, Arteriosclerosis | Phase 4 | Completed | Nabi Biopharmaceuticals | 203 | 2005-01-01 | 2008-01-08 |
| Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis Sevelamer Hydrochloride (Renagel®), Calcium acetate (PhosLo® ) - Peritoneal Dialysis, Chronic Kidney Disease | Phase 3 | Completed | Genzyme, a Sanofi Company | 138 | 2004-12-01 | 2015-03-18 |
Showing 20 of 22. Sign in to see all of them.
Hyperphosphatemia (10) · Renal Insufficiency, Chronic (7) · Renal Insufficiency (4) · Hyperparathyroidism, Secondary (3) · Vascular Calcification (3) · Anemia (1) · Arteriosclerosis (1) · Calcinosis (1) · Hypophosphatemia (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Smallpox (1) · Vascular Diseases (1)
Fresenius Medical Care North America (2) · Gulhane School of Medicine (2) · Nabi Biopharmaceuticals (2) · Akebia Therapeutics (1) · Albany College of Pharmacy and Health Sciences (1) · Ardelyx (1) · Assiut University (1) · Azienda Ospedaliera Sant'Anna (1) · Chugai Pharma Taiwan (1) · Denver Nephrologists, P.C. (1) · Genzyme, a Sanofi Company (1) · Keryx Biopharmaceuticals (1) · Medical Research Council (1) · National Center for Research Resources (NCRR) (1) · Romanian Society of Nephrology (1)
United States (13) · France (2) · Italy (2) · Romania (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Denmark (1) · Germany (1) · Israel (1) · Lithuania (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Russia (1)
Wajeh Y Qunibi, M.D. (2) · Adrian Covic, Prof (1) · Antoinette A. Pragalos, MD (1) · Antonio Bellasi, MD (1) · Chiu-Ching Huang, Professor (1) · Csaba P. Kovesdy, M.D. (1) · Darius L Mason, Pharm.D. (1) · David P Rosenbaum, PhD (1) · Dennis Hruby, PhD (1) · Gabriel Mircescu, Prof (1) · Geoffrey A Block, MD (1) · Jonathan Powell, PhD (1) · Julia B Lewis, MD (1) · Larry A Greenbaum, MD; PhD (1) · Mahmut I Yilmaz (1)
PMID 40576086, PMID 18057307, PMID 18423809, PMID 21324193, PMID 22137672, PMID 26239948, PMID 27007989, PMID 27357090, PMID 29989014, PMID 33766811, PMID 34599865, PMID 38323855